Abstract
The Biopharmaceutics Classification System (BCS) has become widely accepted today in the academic, industrial, and regulatory world. While the initial application of the BCS was to regulatory science bioequivalence (BE) issues and related implications, it has come to be utilized widely by the pharmaceutical industry in drug discovery and development as well. This brief manuscript will relate the story of the BCS development. While much of the ground work for the BCS goes back to the pharmacokinetic and drug absorption research by Gordon Amidon (GLA) in the 1970s and 1980s, the realization of the need for a classification or categorization of drug and drug products for setting dissolution standards became apparent to GLA during his 1990–1991 sabbatical year at the FDA. Initiated at the invitation of the then CEDR director, Dr. Carl Peck, to become a visiting scientist at the FDA, the goal was to promote regulatory research at the FDA, in my case, in biopharmaceutics, and to develop a science-based system to simplify regulatory requirements.
Similar content being viewed by others
References
Amidon GL et al. Analysis of models for determining intestinal wall permeabilities. J Pharm Sci. 1980;69(12):1369–73.
Amidon GL, Sinko PJ, Fleisher D. Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res. 1988;5(10):651–4.
Oh DM, Curl RL, Amidon GL. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res. 1993;10(2):264–70.
Elliott RL, Amidon GL, Lightfoot EN. A convective mass transfer model for determining intestinal wall permeabilities: laminar flow in a circular tube. J Theor Biol. 1980;87(4):757–71.
Sinko PJ, Leesman GD, Amidon GL. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res. 1991;8(8):979–88.
Knutson L et al. Segmental intestinal perfusion. A “new” technique for human studies. Lakartidningen. 1994;91(19):1941–6.
Lennernas H et al. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol. 1993;35(3):243–50.
Lennernas H et al. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res. 1992;9(10):1243–51.
Dressman JB, Amidon GL, Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci. 1985;74(5):588–9.
Amidon GL et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.
CDER/FDA, U.S. Department of Health and Human Services Food and Drug Administration Center for Evaluation and Research (CDER). In: Guidances for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. 2000.
Vidon N et al. Investigation of drug absorption from the gastrointestinal tract of man. II. Metoprolol in the jejunum and ileum. Br J Clin Pharmacol. 1985;19 Suppl 2:107S–12S.
Jobin G et al. Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum. Br J Clin Pharmacol. 1985;19 Suppl 2:97S–105S.
Jobin G et al. Investigation of drug absorption from the gastrointestinal tract of man. V. Effect of the beta-adrenoceptor antagonist, metoprolol, on postprandial gastric function. Br J Clin Pharmacol. 1985;19 Suppl 2:127S–35S.
Hirtz J. The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation. Br J Clin Pharmacol. 1985;19 Suppl 2:77S–83S.
Godbillon J et al. Investigation of drug absorption from the gastrointestinal tract of man. III. Metoprolol in the colon. Br J Clin Pharmacol. 1985;19 Suppl 2:113S–8S.
WHO. WHO Technical report series 937, Annex 7 Multisource (generic) pharmaceutical products. Guidance on registration requirements to establish interchangeability. Geneva, Switzerland; 2006.
Kasim NA et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm. 2004;1(1):85–96.
Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23.
Tsume Y, et al. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci. 2014.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shah, V.P., Amidon, G.L. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability, Pharm Res 12, 413–420, 1995—Backstory of BCS. AAPS J 16, 894–898 (2014). https://doi.org/10.1208/s12248-014-9620-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-014-9620-9